Table 2.
Temporal prevalences of healthcare-acquired ESBL-positive Enterobacteriaceae in hospitals of Latin America.
| Surveillance program | Collection period | Anatomical collection site | Proportion ESBL-positive (total no. isolates) |
|
|---|---|---|---|---|
| E. coli | Klebsiella spp. | |||
| SMART27 | 2004 | Intra-abdominal | 12% | 28% |
| SMART28 | 2005 | Intra-abdominal | 16% (395) | 27% (121) |
| TESTa,31 | 2004–2006 | Blood, respiratory tract, urine, skin, wound, fluids and other defined sources | 14% (326) | 44% (282)b |
| TEST32 | 2004–2010 | Blood, respiratory tract, urine, skin, wound, fluids | 24% (3581) | 35% (2962)b |
| DISN8 | 2007 | Blood, respiratory tract, skin and skin structure, urine | 14% (493) | 44% (350)b |
| SMART29 | 2008 | Intra-abdominal | 27% (504) | 38% (151)b |
| SMART30 | 2008–2009 | Intra-abdominal | 24% (1366) | NR |
| SENTRY33 | 2008–2010 | Blood, skin and soft tissue, lower respiratory tract | 25% (1517) | 53% (1052) |
| SMARTc,36 | 2009–2010 | Urine | 23% | |
ESBL, extended spectrum β-lactamase; DISN, Doripenem International Surveillance Network; NR, not reported; SMART, Study for Monitoring Antimicrobial Resistance Trends; TEST, Tigecycline Evaluation and Surveillance Trial.
a
Most data were collected from intensive care units.
b
K. pneumoniae only.
c
Data collected from 15 sites in Latin America; countries where sites located not specified.36